Cancer Blood Test

MiRNA is Uniquely Suited for Personalized Medicine

Personalized medicine is gaining momentum and changing the landscape of healthcare globally. MiRNA is a novel class of genetic material discovered only at the dawn of the 21st century but has continuously made headlines in biomedical research worldwide. Distinct from DNA mutations, miRNA expression level changes during disease state and offers valuable information in detecting disease onset and monitoring disease progression and recurrence. Unlike other genetic materials, miRNA is exceptional stable and accessible in biofluids, making it an ideal candidate biomarker for non-invasive blood based test. MiRNA research has been growing exponentially worldwide with Frost and Sullivan bullishly projected that “advance in microRNA is predicting future in vitro diagnostic market”.

image

Blood Test - First Line of Screening of Gastric Cancer

image

State-of-the-art Blood Test Workflow

  • Standard Blood Processing

  • Accredited Test Laboratory

  • Actionable Test Results

Gastric Cancer Test Kit

MiRXES Pipeline of Cancer MiRNA Blood Test

    Gastric Cancer miRNA Test

    1. Biomarker Discovery
    2. Biomarker Verification
    3. Analytical Validation
    4. Clinical Validation (N>12,000, MultiCenter)
    Blood Based Gastric Cancer miRNA Test

    (Evidence: 3 case-control cohorts, multi-ethnicity, N>900)

  • Breast Cancer miRNA Test

    1. Biomarker Discovery
    2. Biomarker Verification
    3. Analytical Validation
    4. Clinical Validation (N>2,000, MultiCenter)
    Blood Based Breast Cancer miRNA Test

    (Evidence: 3 case-control cohorts, multi-ethnicity, N>800)

  • Lung Cancer miRNA Test

    1. Biomarker Discovery
    2. Biomarker Verification
    3. Analytical Validation
    4. Clinical Validation (N>5000, MultiCenter)
    Blood Based Lung Cancer miRNA Test

    (Evidence: 3 case-control cohorts, multi-ethnicity, N>1200)

  • Other Cancer miRNA Test

    1. Biomarker Discovery
    2. Biomarker Verification
    3. Analytical Validation
    4. Clinical Validation
    Pipeline Cancer miRNA Tests